標(biāo)題: Titlebook: Combination Treatment in Autoimmune Diseases; W. B. Harrison,B. A. C. Dijkmans Book 2002 Springer-Verlag Berlin Heidelberg 2002 Autoimmune [打印本頁] 作者: FETUS 時(shí)間: 2025-3-21 19:43
書目名稱Combination Treatment in Autoimmune Diseases影響因子(影響力)
書目名稱Combination Treatment in Autoimmune Diseases影響因子(影響力)學(xué)科排名
書目名稱Combination Treatment in Autoimmune Diseases網(wǎng)絡(luò)公開度
書目名稱Combination Treatment in Autoimmune Diseases網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Combination Treatment in Autoimmune Diseases被引頻次
書目名稱Combination Treatment in Autoimmune Diseases被引頻次學(xué)科排名
書目名稱Combination Treatment in Autoimmune Diseases年度引用
書目名稱Combination Treatment in Autoimmune Diseases年度引用學(xué)科排名
書目名稱Combination Treatment in Autoimmune Diseases讀者反饋
書目名稱Combination Treatment in Autoimmune Diseases讀者反饋學(xué)科排名
作者: 情愛 時(shí)間: 2025-3-21 22:20 作者: 品牌 時(shí)間: 2025-3-22 02:54 作者: N斯巴達(dá)人 時(shí)間: 2025-3-22 08:20 作者: 懶洋洋 時(shí)間: 2025-3-22 10:01 作者: perjury 時(shí)間: 2025-3-22 14:01 作者: perjury 時(shí)間: 2025-3-22 19:12
A Survey of IoT Software Platformsincluding RA and osteoarthritis, was nearly $65 billion. Accordingly, the impact of RA and osteoarthritis on resource utilization is enormous [130]. The total yearly direct costs for RA alone in the United States, based on a national community-based sample, are estimated to be $15 billion [130].作者: filial 時(shí)間: 2025-3-23 00:41
Advances in Conceptual Modelinging B cell lymphoproliferative disorders. The correct diagnosis requires evaluation by various specialists [35]. Differential diagnosis includes adverse effects of drugs, chronic viral infection, e.g., hepatitis C virus (HCV) and HIV, sarcoidosis, lipoproteinemias, amyloidosis, lymphomas and age-related glandular degeneration [12].作者: Synovial-Fluid 時(shí)間: 2025-3-23 03:24
Alberto Esteban,Alejandro Maté,Juan Trujillo of diseases. Patients may have more than one symptom at the same time or at different moments during life. A positive family history is an important hallmark of SpA, and reflects its genetic background.作者: Ablation 時(shí)間: 2025-3-23 09:35
Combination therapy for autoimmune diseases: the rheumatoid arthritis modelincluding RA and osteoarthritis, was nearly $65 billion. Accordingly, the impact of RA and osteoarthritis on resource utilization is enormous [130]. The total yearly direct costs for RA alone in the United States, based on a national community-based sample, are estimated to be $15 billion [130].作者: Grasping 時(shí)間: 2025-3-23 11:03 作者: Explosive 時(shí)間: 2025-3-23 17:49
Spondylarthropathies: options for combination therapy of diseases. Patients may have more than one symptom at the same time or at different moments during life. A positive family history is an important hallmark of SpA, and reflects its genetic background.作者: 先驅(qū) 時(shí)間: 2025-3-23 20:24
Christoph G. Schuetz,Michael Schreflale population (6% overall), and an annual prevalence of SSc of 15 cases per 100,000. Data from the UK has previously estimated a much lower prevalence but a comprehensive local study has led to estimates being revised to levels similar to the North American figures [28].作者: COM 時(shí)間: 2025-3-24 01:20
Combination therapies for systemic sclerosisale population (6% overall), and an annual prevalence of SSc of 15 cases per 100,000. Data from the UK has previously estimated a much lower prevalence but a comprehensive local study has led to estimates being revised to levels similar to the North American figures [28].作者: Seizure 時(shí)間: 2025-3-24 03:08 作者: 大喘氣 時(shí)間: 2025-3-24 08:56
A Survey of IoT Software Platformsggressive initial therapy. These adagia have influenced in recent times all fields of medicine, from oncology to infectious diseases and also — the topic of the present edition — the “autoimmune diseases”. As an example of the latter, rheumatoid arthritis (RA) demonstrates how the attitude of physicians has been changed.作者: Ganglion-Cyst 時(shí)間: 2025-3-24 13:18
https://doi.org/10.1007/978-3-319-14139-8ture mortality. Even though methotrexate (MTX) has become a “gold standard” of therapy, its use rarely results in disease remission. The recent introduction of new treatments which offer significant incremental improvements in both efficacy and tolerability argues strongly for utilization of combination therapy.作者: 宴會(huì) 時(shí)間: 2025-3-24 17:15 作者: creditor 時(shí)間: 2025-3-24 22:32 作者: Vo2-Max 時(shí)間: 2025-3-25 00:16 作者: GULP 時(shí)間: 2025-3-25 07:21
Stem cell transplantation for autoimmune diseasesmune process. Haemopoietic stem cell transplantation (HSCT) can therefore be seen as a way of replacing or immunomodulating these cells in the affected tissues and thus ameliorating or even curing the disease. Evidence is now accumulating to suggest that HSCT is a viable and encouraging treatment op作者: Obloquy 時(shí)間: 2025-3-25 08:46 作者: VERT 時(shí)間: 2025-3-25 14:42
Lecture Notes in Computer Scienceonotherapy. Second, more therapy has not been shown to be more toxic. Thus, increasing the doses of combination therapy has become standard, although there is a great debate about whether this should be used as a blanket approach in early disease. A step-up approach (adding in successive therapies f作者: CARE 時(shí)間: 2025-3-25 18:59 作者: Magnificent 時(shí)間: 2025-3-25 23:24 作者: MONY 時(shí)間: 2025-3-26 02:09
he advance of instituting monotherapy with a single optimised disease-modifying anti-rheumatic drug (DMARD) - with methotrexate as prototype agent in RA - adequate disease re- mission is not often achieved, and adverse events may well prevent the use of higher dosages of the single agent in question. Therefor978-3-642-07704-3978-3-662-04759-0作者: Melanocytes 時(shí)間: 2025-3-26 06:39 作者: FLAX 時(shí)間: 2025-3-26 12:02
A Survey of IoT Software Platformsse patients who are rheumatoid factor (RF) positive, have early active disease and have early erosions on X-ray also have a shortened life span [98, 100, 109]. Since RA frequently affects patients during their most productive years, disability can result in major economic loss, especially within 10 作者: irradicable 時(shí)間: 2025-3-26 13:27 作者: 凈禮 時(shí)間: 2025-3-26 20:39 作者: 凹處 時(shí)間: 2025-3-27 00:29 作者: 不發(fā)音 時(shí)間: 2025-3-27 03:19 作者: Shuttle 時(shí)間: 2025-3-27 08:16 作者: 怒目而視 時(shí)間: 2025-3-27 09:26 作者: interpose 時(shí)間: 2025-3-27 14:58
Christoph G. Schuetz,Michael Schreflions are listed in Table 1. There are common features to these disorders and some clinical overlap between them but they can be separated into three main categories, those with skin sclerosis but no vascular or internal organ involvement such as morphea, conditions with vascular manifestations only,作者: Substance 時(shí)間: 2025-3-27 20:48
Advances in Conceptual Modelingne hallmarks of the disease are attested by the focal lymphoid cell infiltration (Fig. 1) of the exocrine glands and various autoantibodies [28]. The clinical spectrum of the syndrome extends from an organ-specific autoimmune disorder to a systemic process. In addition, features of SS are frequently作者: FLAIL 時(shí)間: 2025-3-28 00:53 作者: calumniate 時(shí)間: 2025-3-28 02:15 作者: 圓桶 時(shí)間: 2025-3-28 09:27 作者: 土產(chǎn) 時(shí)間: 2025-3-28 14:05 作者: 緩解 時(shí)間: 2025-3-28 16:54
http://image.papertrans.cn/c/image/229863.jpg作者: 發(fā)源 時(shí)間: 2025-3-28 22:43
https://doi.org/10.1007/978-3-030-87049-2. This article outlines possible strategies based on the primary choice between maximization of efficacy or minimization of toxicity. Strategies are illustrated with examples from trial experience in the field of rheumatoid arthritis.作者: irradicable 時(shí)間: 2025-3-29 02:32 作者: 衰弱的心 時(shí)間: 2025-3-29 04:06 作者: 周興旺 時(shí)間: 2025-3-29 10:29
Methodology of combination trials. This article outlines possible strategies based on the primary choice between maximization of efficacy or minimization of toxicity. Strategies are illustrated with examples from trial experience in the field of rheumatoid arthritis.作者: MURKY 時(shí)間: 2025-3-29 11:29 作者: Abnormal 時(shí)間: 2025-3-29 18:24
Combination treatment in autoimmune diseases: systemic lupus erythematosuses and other immunological abnormalities, which may affect the skin, joints, lungs, heart, serous membranes, nervous system and other organs. Renal involvement is common and can greatly affect the prognosis. Table 1 summarises its main clinical characteristics.作者: Bravura 時(shí)間: 2025-3-29 22:42 作者: Allergic 時(shí)間: 2025-3-30 01:06
978-3-642-07704-3Springer-Verlag Berlin Heidelberg 2002作者: 可觸知 時(shí)間: 2025-3-30 04:53
Combination treatment in autoimmune diseases — Introductiontivity of the disease, to avoid further damage and to maintain quality of life. Apart from the principle “Treat now, not later”, emphasis is laid on aggressive initial therapy. These adagia have influenced in recent times all fields of medicine, from oncology to infectious diseases and also — the to作者: 密碼 時(shí)間: 2025-3-30 08:19 作者: Offset 時(shí)間: 2025-3-30 14:22 作者: AWL 時(shí)間: 2025-3-30 19:50
